Evidence map›Paper›PMID 25793483›Full record

SynthesisJournal of women's health (2002)2015

Sex differences in device therapy for heart failure: utilization, outcomes, and adverse events.

Naomi D Herz, Joseph Engeda, Robbert Zusterzeel, William E Sanders, Kathryn M O'Callaghan, David G Strauss, Samantha B Jacobs, Kimberly A Selzman, Ileana L Piña, Daniel A Caños

Abstract readSystematic Review
In one paragraph

Synthesis in Journal of women's health (2002), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Naomi D HerzCenter for Devices and Radiological Health, United States Food and Drug Administration , Silver Spring, Maryland.
Joseph Engeda
Robbert Zusterzeel
William E Sanders
Kathryn M O'Callaghan
David G Strauss
Samantha B Jacobs
Kimberly A Selzman
Ileana L Piña
Daniel A Caños
Center for Devices and Radiological Health · USUnited States Food and Drug Administration · US

Funding

Cardiovascular Epidemiology Training GrantT32HL007055 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Wayne D. Rosamond · 1986 to 2026
$10.0M
NHLBI NIH HHS T32 HL007055
6 · The paper itself

Abstract

backgroundMultiple studies of heart failure patients demonstrated significant improvement in exercise capacity, quality of life, cardiac left ventricular function, and survival from cardiac resynchronization therapy (CRT), but the underenrollment of women in these studies is notable. Etiological and pathophysiological differences may result in different outcomes in response to this treatment by sex. The observed disproportionate representation of women suggests that many women with heart failure either do not meet current clinical criteria to receive CRT in trials or are not properly recruited and maintained in these studies.

methodsWe performed a systematic literature review through May 2014 of clinical trials and registries of CRT use that stratified outcomes by sex or reported percent women included. One-hundred eighty-three studies contained sex-specific information.

resultsNinety percent of the studies evaluated included ≤ 35% women. Fifty-six articles included effectiveness data that reported response with regard to specific outcome parameters. When compared with men, women exhibited more dramatic improvement in specific parameters. In the studies reporting hazard ratios for hospitalization or death, women generally had greater benefit from CRT.

conclusionsOur review confirms women are markedly underrepresented in CRT trials, and when a CRT device is implanted, women have a therapeutic response that is equivalent to or better than in men, while there is no difference in adverse events reported by sex.

Indexed as

Cardiac Resynchronization TherapyQuality of LifeSex FactorsAgedCardiac Resynchronization Therapy DevicesFemaleHeart FailureHospitalizationHumansMaleMiddle AgedRecovery of FunctionSex CharacteristicsSurvival RateTreatment Outcome

Identifiers

PMID25793483
PMCPMC4808287
OpenAlexW1987428028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.